Literature DB >> 7832132

Coronary microvascular response to intracoronary administration of nicorandil.

M Hongo1, H Takenaka, S Uchikawa, T Nakatsuka, N Watanabe, M Sekiguchi.   

Abstract

Nicorandil is an antianginal drug that causes potent coronary vasodilation of both epicardial and resistance vessels. To measure the dose-response kinetics of bolus injections of intracoronary nicorandil and to compare the vasodilatory response to nicorandil with that of intracoronary papaverine in humans, coronary blood flow velocity was measured in 30 patients using a 3Fr intravascular Doppler catheter. Continuous intravenous nitroglycerin 6 to 8 micrograms/min was infused to achieve maximal vasodilation of the epicardial vessels. Bolus doses of nicorandil dissolved in warmed saline solution were injected into the left (0.1, 0.2, 0.5, 1.0, 1.5, and 2.0 mg) and right (0.1, 0.2, 0.4, 0.8, 1.0, and 1.5 mg) coronary arteries. Intracoronary nicorandil caused a dose-dependent increase in coronary flow velocity and a decrease in coronary vascular resistance. Maximal vasodilatory effects equivalent to those obtained with 12 +/- 2 mg of intracoronary papaverine were induced with nicorandil 1.5 mg in the left coronary artery, and effects similar to those of 10 +/- 2 mg of papaverine were produced with nicorandil 1.0 mg in the right coronary artery. The time from injection of nicorandil to the onset of maximal hyperemia and duration of hyperemia were significantly shorter after nicorandil than after papaverine in both coronary arteries. Each dose of nicorandil produced no clinical symptoms and fewer changes in systemic hemodynamics and electrocardiographic QT intervals than did papaverine. These results suggest that a bolus administration of intracoronary nicorandil can safely, quickly, and reliably induce maximal coronary hyperemia comparable to that achieved with intracoronary papaverine in humans.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7832132     DOI: 10.1016/0002-9149(95)80029-r

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Usefulness of myocardial contrast echocardiography with nicorandil stress for the detection of coronary artery stenosis.

Authors:  K Okajima; Y Kawase; N Matsushita; S Iwata; A Doi; T Hasegawa; K Hato; M Nishimoto; Y Abe; M Yoshiyama; J Yoshikawa
Journal:  Heart       Date:  2006-09       Impact factor: 5.994

2.  [Nicorandil: acute hemodynamic effects of 2 different oral doses of a potassium channel opener in patients with coronary heart disease].

Authors:  C Bickel; H J Rupprecht; A Tyrtania; J Rörig; J Meyer
Journal:  Med Klin (Munich)       Date:  1999-02-15

Review 3.  Use of nicorandil in cardiovascular disease and its optimization.

Authors:  Shigeo Horinaka
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

4.  Estimation of coronary flow reserve by intracoronary administration of nicorandil: comparison with intracoronary administration of papaverine.

Authors:  F Inoue; T Hashimoto; S Fujimoto; S Uemura; A Kawamoto; K Dohi
Journal:  Heart Vessels       Date:  1998       Impact factor: 2.037

5.  Feasibility and safety of intracoronary nicorandil infusion as a novel hyperemic agent for fractional flow reserve measurements.

Authors:  Daiki Kato; Hiroaki Takashima; Katsuhisa Waseda; Akiyoshi Kurita; Yasuo Kuroda; Takashi Kosaka; Yasushi Kuhara; Hirohiko Ando; Kazuyuki Maeda; Soichiro Kumagai; Shinichiro Sakurai; Akihiro Suzuki; Yukiko Toda; Atsushi Watanabe; Shigeko Sato; Masanobu Fujimoto; Tomofumi Mizuno; Tetsuya Amano
Journal:  Heart Vessels       Date:  2014-04-19       Impact factor: 2.037

6.  ST elevation after intracoronary administration of Papaverine for fractional flow reserve estimation.

Authors:  R K Jain; Nishad S Chitnis; B Hygriv Rao
Journal:  Indian Heart J       Date:  2014-04-18

Review 7.  Microvascular angina: angina that predominantly affects women.

Authors:  Jin Joo Park; Sung-Ji Park; Dong-Ju Choi
Journal:  Korean J Intern Med       Date:  2015-02-27       Impact factor: 2.884

8.  Cardioprotective Effects of Nicorandil on Coronary Heart Disease Patients Undergoing Elective Percutaneous Coronary Intervention.

Authors:  Zhihua Pang; Wei Zhao; Zhuhua Yao
Journal:  Med Sci Monit       Date:  2017-06-15

9.  Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention.

Authors:  Jing Yang; Jidong Zhang; Wei Cui; Fan Liu; Ruiqin Xie; Xiaohong Yang; Guoqiang Gu; Hongmei Zheng; Jingchao Lu; Xiuchun Yang; Guangming Zhang; Qian Wang; Xue Geng
Journal:  Anatol J Cardiol       Date:  2014-04-16       Impact factor: 1.596

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.